Lessons learned from trends in psychotropic drug expenditures in a Canadian province

Carolyn S Dewa, P. Goering

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Although prescription drug prices are lower in Canada than in the United States, trends indicate that there has nevertheless been a steep increase in expenditures on psychotropic drugs. Between 1992 and 1998, such expenditures increased by 216 percent; 61 percent of these expenditures were on antidepressants, 33 percent on antipsychotics, and less than 7 percent on anxiolytics. Most of the increase in costs in Canada is attributable to a greater use of newer agents and the higher prices of these agents. These trends are a reminder not only that the use of newer, more expensive psychotherapeutic agents has become a widely embraced part of care but also that lower drug prices do not necessarily insulate a health care system from rising expenditures. The authors' findings prompt the questions of whether the use of these newer agents meets practice guidelines and whether there are ways to control the increases in drug expenditures while ensuring high-quality care.

Original languageEnglish (US)
Pages (from-to)1245-1247
Number of pages3
JournalPsychiatric Services
Volume52
Issue number9
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Psychotropic Drugs
Health Expenditures
Canada
Prescription Drugs
Quality of Health Care
Anti-Anxiety Agents
Practice Guidelines
Pharmaceutical Preparations
Antidepressive Agents
Antipsychotic Agents
Delivery of Health Care
Costs and Cost Analysis

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Lessons learned from trends in psychotropic drug expenditures in a Canadian province. / Dewa, Carolyn S; Goering, P.

In: Psychiatric Services, Vol. 52, No. 9, 2001, p. 1245-1247.

Research output: Contribution to journalArticle

@article{3c7052d0eaaf46f1bef961a743cb4e1f,
title = "Lessons learned from trends in psychotropic drug expenditures in a Canadian province",
abstract = "Although prescription drug prices are lower in Canada than in the United States, trends indicate that there has nevertheless been a steep increase in expenditures on psychotropic drugs. Between 1992 and 1998, such expenditures increased by 216 percent; 61 percent of these expenditures were on antidepressants, 33 percent on antipsychotics, and less than 7 percent on anxiolytics. Most of the increase in costs in Canada is attributable to a greater use of newer agents and the higher prices of these agents. These trends are a reminder not only that the use of newer, more expensive psychotherapeutic agents has become a widely embraced part of care but also that lower drug prices do not necessarily insulate a health care system from rising expenditures. The authors' findings prompt the questions of whether the use of these newer agents meets practice guidelines and whether there are ways to control the increases in drug expenditures while ensuring high-quality care.",
author = "Dewa, {Carolyn S} and P. Goering",
year = "2001",
doi = "10.1176/appi.ps.52.9.1245",
language = "English (US)",
volume = "52",
pages = "1245--1247",
journal = "Psychiatric Services",
issn = "1075-2730",
publisher = "American Psychiatric Association",
number = "9",

}

TY - JOUR

T1 - Lessons learned from trends in psychotropic drug expenditures in a Canadian province

AU - Dewa, Carolyn S

AU - Goering, P.

PY - 2001

Y1 - 2001

N2 - Although prescription drug prices are lower in Canada than in the United States, trends indicate that there has nevertheless been a steep increase in expenditures on psychotropic drugs. Between 1992 and 1998, such expenditures increased by 216 percent; 61 percent of these expenditures were on antidepressants, 33 percent on antipsychotics, and less than 7 percent on anxiolytics. Most of the increase in costs in Canada is attributable to a greater use of newer agents and the higher prices of these agents. These trends are a reminder not only that the use of newer, more expensive psychotherapeutic agents has become a widely embraced part of care but also that lower drug prices do not necessarily insulate a health care system from rising expenditures. The authors' findings prompt the questions of whether the use of these newer agents meets practice guidelines and whether there are ways to control the increases in drug expenditures while ensuring high-quality care.

AB - Although prescription drug prices are lower in Canada than in the United States, trends indicate that there has nevertheless been a steep increase in expenditures on psychotropic drugs. Between 1992 and 1998, such expenditures increased by 216 percent; 61 percent of these expenditures were on antidepressants, 33 percent on antipsychotics, and less than 7 percent on anxiolytics. Most of the increase in costs in Canada is attributable to a greater use of newer agents and the higher prices of these agents. These trends are a reminder not only that the use of newer, more expensive psychotherapeutic agents has become a widely embraced part of care but also that lower drug prices do not necessarily insulate a health care system from rising expenditures. The authors' findings prompt the questions of whether the use of these newer agents meets practice guidelines and whether there are ways to control the increases in drug expenditures while ensuring high-quality care.

UR - http://www.scopus.com/inward/record.url?scp=0034846167&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034846167&partnerID=8YFLogxK

U2 - 10.1176/appi.ps.52.9.1245

DO - 10.1176/appi.ps.52.9.1245

M3 - Article

VL - 52

SP - 1245

EP - 1247

JO - Psychiatric Services

JF - Psychiatric Services

SN - 1075-2730

IS - 9

ER -